IMUC Signs Research Agreement With George Mason University
Posted on: Friday, 20 June 2008, 12:00 CDT
ImmunoCellular Therapeutics has signed a research agreement with George Mason University for the development of a blood test to detect small cell lung cancer and pancreatic cancer using IMUC's monoclonal antibody technology.
The blood-based test would be designed to look for certain markers for the cancers potentially allowing for early detection of these cancers as well as assisting the selection of patients most likely to respond to the company's monoclonal antibody therapy, ICT-109.
ICT-109, the company's lead antibody, is a monoclonal antibody targeting small cell lung cancer and pancreatic cancer. This candidate is currently in pre-clinical development, and the company plans to couple it with a diagnostic kit to prescreen patients for the specific antigens that bind to ICT-109.
Emmanuel Petricoin, co-director of center for applied proteomics and molecular medicine at George Mason University, said: "We look forward to working with ImmunoCellular Therapeutics and working toward the validation and verification of their candidate biomarkers, as we are intrigued by the preclinical data collected to date."
Source: Datamonitor
Related Articles
- ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours
- ImmunoCellular Therapeutics Granted Patents Covering Its Lead Monoclonal Antibody Cancer Product Candidate
- ImmunoCellular Therapeutics Announces Ability to Characterize Distinct Antigens Between Cancers Using Monoclonal Antibody Technology
- CG Therapeutics and University of Washington Announce Formation of Joint Monoclonal Antibody Program
- CancerVax Compound Approved for Human Trials
- Advances in Genetic Engineering Stimulate Interest in Therapeutic Monoclonal Antibodies
- First Production of Human Monoclonal Antibodies in Chicken Eggs Published in Nature Biotechnology
- GTC Biotherapeutics and Scancell Collaborate on SC101 Antibody
- Correlation Between Serum Levels of Free Light Chain and Phenotype of Plasma Cells in Bone Marrow in Primary AL Amyloidosis
- Perspectives on Cancer Therapy With Radiolabeled Monoclonal Antibodies
 |
 |
User Comments (0)
RSS Feeds